Engineering a dual vaccine against COVID-19 and tuberculosis
Frontiers in Cellular and Infection Microbiology, 2023 The COVID-19 pandemic, caused by SARS-CoV-2 virus, has been one of the top public health threats across the world over the past three years. Mycobacterium bovis BCG is currently the only licensed vaccine for tuberculosis, one of the deadliest infectious ...
Carlyn Monèt Guthrie +11 more
doaj +1 more source
Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. [PDF]
PLoS Neglected Tropical Diseases, 2016 Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells ...
Bryan E Hart, Sunhee Lee
doaj +1 more source
Protease-Based Subunit Vaccine in Mice Boosts BCG Protection against Mycobacterium tuberculosis
Vaccines, 2022 The significant number of people with latent and active tuberculosis infection requires further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is the only approved vaccine against this disease.
Ana Paula Junqueira-Kipnis +7 more
doaj +1 more source
The use of directed evolution to create a stable and immunogenic recombinant BCG expressing a modified HIV-1 Gag antigen. [PDF]
PLoS ONE, 2014 Numerous features make Mycobacterium bovis BCG an attractive vaccine vector for HIV. It has a good safety profile, it elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable.
Rosamund Chapman +8 more
doaj +1 more source
Vaccines, 2021 The only currently available anti-tuberculosis vaccine, Bacillus Calmette–Guérin (BCG), has been reported to also protect against unrelated diseases, including inflammatory diseases such as allergic asthma. Recombinant BCG strains that produce IL-18 have
Magdalena Kowalewicz-Kulbat +7 more
doaj +1 more source
Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection. [PDF]
PLoS ONE, 2010 M. bovis Bacille Calmette-Guérin (BCG), currently the only available vaccine against tuberculosis (TB), fails to adequately protect individuals from active and latent TB infection.
Scott T Nolan, Gyanu Lamichhane
doaj +1 more source
The glycosylated Rv1860 protein of Mycobacterium tuberculosis inhibits dendritic cell mediated TH1 and TH17 polarization of T cells and abrogates protective immunity conferred by BCG. [PDF]
PLoS Pathogens, 2014 We previously reported interferon gamma secretion by human CD4⁺ and CD8⁺ T cells in response to recombinant E. coli-expressed Rv1860 protein of Mycobacterium tuberculosis (MTB) as well as protection of guinea pigs against a challenge with virulent MTB ...
Vijaya Satchidanandam +5 more
doaj +1 more source
mBio, 2022 Mycobacterium tuberculosis infects approximately one-third of the world's population, causing active tuberculosis (TB) in ~10 million people and death in ~1.5 million people annually. A potent vaccine is needed to boost the level of immunity conferred by
Qingmei Jia +3 more
doaj +1 more source
Frontiers in Immunology, 2020 While Baccillus Calmette-Guerin (BCG) is used worldwide, tuberculosis (TB) is still a global concern due to the poor efficacy of BCG. Novel vaccine candidates are therefore urgently required.
Si-Jing Liu +12 more
doaj +1 more source
Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine
mBio, 2016 Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002)
Helen A. Fletcher
doaj +1 more source